| Date |
Research Question / Title |
Unique ID |
Research Team |
|
October 29, 2021
|
Long COVID: What does it mean for the healthcare system and programs to deal with it?
|
EOC021901v2 RR
|
EOC
|
|
October 7, 2021
|
What is the current evidence and recommendations regarding COVID-19 vaccine booster shots (exceeding 2 doses) for the general population?
|
EOC210902 RR
|
EOC
|
|
July 12, 2021
|
What are long COVID's demands on the healthcare system, and its
severity of the illness?
|
EPM210602 RR
|
Epidemiology & Modelling
|
|
July 9, 2021
|
What is the incidence and duration of Long COVID cases?
|
EPM210601 RR
|
Epidemiology & Modelling
|
|
April 21, 2021
|
What are the risks or benefits of extended intervals between doses of COVID-19 vaccines compared to recommended dosing in extremely vulnerable populations?
|
EOC210302 RR
|
EOC
|
|
April 6, 2021
|
How to deliver remote ICU care for COVID-19 patients to avoid/prevent transfer from smaller communities to tertiary care hospitals
|
CC210301 RR
|
Critical Care
|
|
February 27, 2021
|
What is the final disposition of post-COVID patients who require chronic ventilation in the ICU?
|
CC011101 RR
|
Critical Care
|
|
January 22, 2021
|
What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? [Update]
|
EOC062201v2 RR
|
EOC
|
|
January 13, 2021
|
What are the outcomes of ECMO and COVID, particularly in small centers?
|
EOC011101 RR
|
EOC
|
|
December 9, 2020
|
What are the predictors of mortality in hospitalized COVID-19 patients?
|
CC120402 RR
|
Critical Care
|
|
November 25, 2020
|
Are probiotics effective for prevention or therapy of respiratory tract infections in all ages?
|
EOC111201 RR
|
EOC
|
|
November 2, 2020
|
What is the risk of reinfection from COVID-19? [Update]
|
EOC032401v3 RR
|
EOC
|
|
September 29, 2020
|
What is the evidence that runny nose or sneezing are symptoms of COVID-19?
|
EOC092401 RR
|
EOC
|
|
May 22, 2020
|
In similar jurisdictions experiencing the COVID-19 pandemic, what is the proportion of patients receiving non-invasive ventilation versus those receiving intermittent mandatory ventilation?
|
EOC052102 RR
|
EOC
|
|
May 19, 2020
|
What are the risk factors for severity and death associated with COVID-19?
|
EPM050901 RR
|
Epidemiology & Modelling
|
|
May 19, 2020
|
What is the relationship between antibody development and viral shedding and infectiousness? [Update]
|
LAB041601v2 RR
|
Laboratory
|
|
May 11, 2020
|
What percentage of COVID-19 patients have hyposmia or anosmia?
|
EOC033102 RR
|
EOC
|
|
May 8, 2020
|
What proportion of disease transmission is due to asymptomatic, pre-symptomatic and symptomatic cases? [Update]
|
LAB040701v2 RR
|
Laboratory
|
|
April 15, 2020
|
At what time in the disease timeline of COVID-19 do antibodies develop?
|
LAB041402 RR
|
Laboratory
|
|
April 11, 2020
|
Is the IgM or IgG immune response protective?
|
LAB040803 RR
|
Laboratory
|
